Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19630614 | 0.89 | APP (0.59) | APPCYP1A2ALDH1A1GAAHTT | |
| SCHEMBL31115697 | 0.83 | APP (1.00) | APPCYP1A2RAB9ALMNAALDH1A1 | |
| SCHEMBL563392 | 0.83 | APP (1.00) | APPCYP1A2RAB9ALMNAALDH1A1 | |
| SCHEMBL3974521 | 0.81 | APP (0.72) | APPCYP1A2ALDH1A1GAAPOLB | |
| SCHEMBL10167882 | 0.78 | APP (1.00) | APPCYP1A2RAB9ANPC1 | |
| SCHEMBL21211676 | 0.78 | APP (0.70) | APPCYP1A2RAB9AALDH1A1GAA | |
| SCHEMBL18932158 | 0.77 | APP (0.74) | APPCYP1A2LMNAALDH1A1GAA | |
| SCHEMBL20437651 | 0.77 | APP (0.73) | APPCYP1A2RAB9AALDH1A1GAA | |
| SCHEMBL15217855 | 0.77 | APP (0.65) | APPCYP1A2RAB9AALDH1A1GAA | |
| SCHEMBL19630632 | 0.76 | APP (0.56) | APPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334865-A1 | DDR2 INHIBITORS AND METHODS OF USING | WASHINGTON UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334865-A1 | DDR2 INHIBITORS AND METHODS OF USING | DDR2, DDR1, DDRGK1 | APP 3057/4885CYP1A2 4799/4885RAB9A 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.